title: [The "other induction"--experiences and consequences in 281 deliveries following intravaginal administration of PGE2 tablets].
abstract: 186 patients have been included prospectively in a study, aimed at analysing the course of birth after induction with 3 mg PGE2-tablets given intravaginally. These data are compared with those gained from a retrospective analysis of 95 patients using a dose of 2 mg. The total of the births within our clinic in 1986/87 functions as controls. Although in every case there has been an urgent need for the termination of pregnancy and there have been also unfavourable cervix findings in the 3 mg group, no differences could be observed in comparison to the control group concerning duration of cervical dilatation and expulsion, as well as foetal outcome parameters. When comparing the 2 mg and 3 mg groups, a certain superiority of the 3 mg dosage could be noted, leading to the opinion, that trial dosages of less than 3 mg should be abandoned. C-section rate was lowest and spontaneous birth rate was highest in the 3 mg group as compared to the 2 mg and the control groups. Permanent CTG-monitoring was not necessary. CTG-controls after 2 and 6 hours proved to be sufficient. Uterine hyperstimulation occurred in 2.1% of cases in both groups. In every case, prompt antagonization by means of high dose betamimetic therapy could be achieved. Due to reducing maternal and foetal side effects, the maximal mobility of the mother after tablet application, as well as, for the smooth congruence of cervical ripening and labour induction, the clinical use of the 3 mg tablet is a modern alternative to the classic oxytocin induction.
authors.affiliation: Klinikum Mannheim, Frauenklinik, Fakultät für Klinische Medizin, Universität Heidelberg.
authors.forename: A
authors.initials: A
authors.lastname: Wischnik
authors.forename: A
authors.initials: A
authors.lastname: Hettenbach
authors.forename: F
authors.initials: F
authors.lastname: Melchert
mesh_terms: D000282:Administration, Intravaginal; D002986:Clinical Trials as Topic; D015232:Dinoprostone / Q000008:administration & dosage* / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D005260:Female; D005322:Premature Rupture of Fetal Membranes / Q000628:therapy; D006801:Humans; D007231:Infant, Newborn; D007751:Labor, Induced / Q000379:methods*; D011247:Pregnancy; D011273:Pregnancy, Prolonged; D011446:Prospective Studies; D012189:Retrospective Studies; D014590:Uterine Contraction / Q000187:drug effects
chemical_list: D015232:Dinoprostone
vernacular_title: Die "andere Einleitung"--Erfahrungen und Konsequenzen aus 281 Geburten nach intravaginaler Gabe von PGE2-Tabletten.